Keith Bruce Pfister

USPTO Granted Patents = 31 (Patent Applications = 12)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 13)

Average Co-Inventor Count = 11.2

ph-index = 9

Forward Citations = 333(Granted Patents)

Location History:

El Cerrito, CA (US) (2002 - 2006)
San Ramon, CA (US) (2006 - 2022)
Emeryville, CA (US) (2010 - 2024)

Company Filing History:

Novartis Vaccines & Diagnostics, Gmbh

University of Washington

patents

5. 2 out of 346

Katholieke Universiteit Leuven

patents

6. 2 out of 624

Korea Research Institute of Chemical Technology

patents

7. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12286423 - Antiviral 1,3-di-oxo-indene compounds (2025-04-29),

2. 12083092 - Antiviral 1,3-di-oxo-indene compounds (2024-09-10),

3. 11234977 - Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals (2022-02-01),

4. 10975078 - Fused indazole pyridone compounds as antivirals (2021-04-13),

5. 10660888 - Aminoheteroaryl benzamides as kinase inhibitors (2020-05-26),

6. 10301312 - Fused indazole pyridone compounds as antivirals (2019-05-28),

7. 10188649 - Aminoheteroaryl benzamides as kinase inhibitors (2019-01-29),

8. 9763937 - Aminoheteroaryl benzamides as kinase inhibitors (2017-09-19),

9. 9242996 - Aminoheteroaryl benzamides as kinase inhibitors (2016-01-26),

10. 8957068 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2015-02-17),

11. 8778951 - Heteroaryl compounds and their uses (2014-07-15),

12. 8710048 - 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling (2014-04-29),

13. 8563549 - Pyrimidine derivatives used as PI-3 kinase inhibitors (2013-10-22),

14. 8415381 - Heteroaryl compounds and their uses (2013-04-09),

15. 8293769 - CSF-1R inhibitors, compositions, and methods of use (2012-10-23),

Title: Keith Bruce Pfister: Pioneering Innovations in Antiviral Compounds

Introduction: Keith Bruce Pfister, a renowned inventor based in San Ramon, CA (US), has made significant contributions to the field of pharmaceuticals with his groundbreaking antiviral compounds. With an impressive portfolio of 29 patents, Pfister's work focuses on developing novel solutions for treating viral infections, particularly hepatitis B virus (HBV).

Latest Patents: Pfister's recent patents include "Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals" and "Fused indazole pyridone compounds as antivirals". These compounds, along with their pharmaceutical compositions, have shown promising results in treating HBV infections and reducing associated serious conditions.

Career Highlights: Pfister has garnered extensive experience working with industry giants such as Novartis Ag and Novartis Vaccines & Diagnostics, GmbH. His innovative approach to drug development has led to the creation of impactful antiviral treatments that have the potential to revolutionize the field of medicine.

Collaborations: Throughout his career, Pfister has collaborated with esteemed professionals in the industry, including Allan S Wagman and Simon C Ng. These collaborations have played a crucial role in advancing the research and development of antiviral compounds, further solidifying Pfister's reputation as a leading figure in the pharmaceutical sector.

Conclusion: Keith Bruce Pfister's dedication to pioneering innovations in antiviral compounds has positioned him as a trailblazer in the field of pharmaceutical research. His relentless pursuit of creating solutions for challenging viral infections underscores his commitment to improving global healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.